Nature Communications (May 2021)
Chromosomal copy number heterogeneity predicts survival rates across cancers
- Erik van Dijk,
- Tom van den Bosch,
- Kristiaan J. Lenos,
- Khalid El Makrini,
- Lisanne E. Nijman,
- Hendrik F. B. van Essen,
- Nico Lansu,
- Michiel Boekhout,
- Joris H. Hageman,
- Rebecca C. Fitzgerald,
- Cornelis J. A. Punt,
- Jurriaan B. Tuynman,
- Hugo J. G. Snippert,
- Geert J. P. L. Kops,
- Jan Paul Medema,
- Bauke Ylstra,
- Louis Vermeulen,
- Daniël M. Miedema
Affiliations
- Erik van Dijk
- Department of Pathology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam
- Tom van den Bosch
- LEXOR, Center for Experimental and Molecular Medicine, Cancer Center Amsterdam and Amsterdam Gastroenterology & Metabolism, Amsterdam UMC, University of Amsterdam
- Kristiaan J. Lenos
- LEXOR, Center for Experimental and Molecular Medicine, Cancer Center Amsterdam and Amsterdam Gastroenterology & Metabolism, Amsterdam UMC, University of Amsterdam
- Khalid El Makrini
- LEXOR, Center for Experimental and Molecular Medicine, Cancer Center Amsterdam and Amsterdam Gastroenterology & Metabolism, Amsterdam UMC, University of Amsterdam
- Lisanne E. Nijman
- LEXOR, Center for Experimental and Molecular Medicine, Cancer Center Amsterdam and Amsterdam Gastroenterology & Metabolism, Amsterdam UMC, University of Amsterdam
- Hendrik F. B. van Essen
- Department of Pathology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam
- Nico Lansu
- Oncode Institute
- Michiel Boekhout
- Oncode Institute
- Joris H. Hageman
- Oncode Institute
- Rebecca C. Fitzgerald
- MRC Cancer Unit, University of Cambridge
- Cornelis J. A. Punt
- Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht
- Jurriaan B. Tuynman
- Department of Surgery, Amsterdam UMC, Vrije Universiteit Amsterdam
- Hugo J. G. Snippert
- Oncode Institute
- Geert J. P. L. Kops
- Oncode Institute
- Jan Paul Medema
- LEXOR, Center for Experimental and Molecular Medicine, Cancer Center Amsterdam and Amsterdam Gastroenterology & Metabolism, Amsterdam UMC, University of Amsterdam
- Bauke Ylstra
- Department of Pathology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam
- Louis Vermeulen
- LEXOR, Center for Experimental and Molecular Medicine, Cancer Center Amsterdam and Amsterdam Gastroenterology & Metabolism, Amsterdam UMC, University of Amsterdam
- Daniël M. Miedema
- LEXOR, Center for Experimental and Molecular Medicine, Cancer Center Amsterdam and Amsterdam Gastroenterology & Metabolism, Amsterdam UMC, University of Amsterdam
- DOI
- https://doi.org/10.1038/s41467-021-23384-6
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 12
Abstract
Intratumour heterogeneity (ITH) is associated with worse prognosis in cancer, and efficient frameworks to measure it are needed. Here the authors develop a method to estimate copy number heterogeneity, and propose that it is driven by chromosomal instability and can predict pan-cancer survival.
